Apixaban as therapeutic option in nephropathy patients with heparin-induced thrombocytopenia (HIT);Apixaban como opción terapéutica en el paciente nefrópata con trombocitopenia inducida por heparina (TIH)

Gaceta Medica de Mexico

Volumn 151, Issue 6, 2015, Pages 798-801

  Delgado García, Guillermo ^a   Monreal Robles, Roberto ^a   Gallegos Arguijo, Daniel ^a   Marfil Rivera, Javier ^b  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Anticoagulants therapeutic use; Apixaban; Chronic kidney disease; Deep venous thrombosis; Heparin adverse effects; Thrombocytopenia chemically induced; Thrombocytopenia therapy

Indexed keywords

APIXABAN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ARTICLE; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY DISEASE; CASE REPORT; CHEMICALLY INDUCED; FEMALE; MIDDLE AGED; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; THROMBOCYTOPENIA;

ANTICOAGULANTS; FACTOR XA INHIBITORS; FEMALE; HEPARIN; HUMANS; MIDDLE AGED; PYRAZOLES; PYRIDONES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; THROMBOCYTOPENIA;

EID: 84957888157     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost. 2014;40(1): 106-14.
2. Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood. 2012;119(10):2209-18.
3. Goździkiewicz J, Borawski J, Myśliwiec M. Treatment of heparin-induced thrombocytopenia type II in hemodialysis patients: the search for a Holy Grail continues. Clin Appl Thromb Hemost. 2007;13(1):110-1.
4. Syed S, Reilly RF. Heparin-induced thrombocytopenia: a renal perspective. Nat Rev Nephrol. 2009;5(9):501-11.
5. Hutchison CA, Dasgupta I. National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant. 2007;22(6):1680-4.
6. Lee GM, Arepally GM. Diagnosis and management of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):541-63.
7. Eliquis[package insert]. Princeton, New Jersey: Bristol-Meyers Squibb; 2012 [Revised: 01/2014].
8. Walenga JM, Prechel M, Hoppensteadt D, et al. Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. 2013;19(5):482-7.
9. Gafter U, Bessler H, Malachi T, et al. Platelet count and thrombopoietic activity in patients with chronic renal failure. Nephron. 1987;45(3): 207-10.
10. Dorgalaleh A, Mahmudi M, Tabibian S, et al. Anemia and thrombocytopenia in acute and chronic renal failure. Int J Hematol Oncol Stem Cell Res. 2013;7(4):34-9.
11. Ho SJ, Gemmell R, Brighton TA. Platelet function testing in uraemic patients. Hematology. 2008;13(1):49-58.
12. Kim HY, Oak CY, Kim MJ, et al. Prevalence and associations for abnormal bleeding times in patients with renal insufficiency. Platelets. 2013;24(3):213-8.
13. Canaud B, Polito-Bouloux C, Garred LJ, et al. Recombinant human erythropoietin: 18 months’ experience in hemodialysis patients. Am J Kidney Dis. 1990;15(2):169-75.
14. Thachil J, Szeki I. Erythropoietin corrects thrombocytopenia. Am J Med. 2013;126(10):e3-4.